A Study to Evaluate ALN-2232 in Participants With Obesity
Recruiting
Phase 1
Phase 2
Interventional Study
Obesity
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 156 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to:
* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity
* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity
* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-ini…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
All Parts:
* Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2
* Has a hemoglobin A1c (HbA1c) \<6.5%
Exclusion Criteria:
All Parts:
* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise partici…
Contacts